Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancerReport as inadecuate




Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer - Download this document for free, or read online. Document in PDF available to download.

SpringerPlus

, 5:1889

UrologyMedicineUrology

Abstract

BackgroundThe platelet–lymphocyte ratio PLR and neutrophil–lymphocyte ratio NLR have been reported as prognostic factors in various cancers, but their roles in metastatic renal cell cancer mRCC remain unclear. We investigated the significance of PLR and NLR, along with that of established prognostic factors, in mRCC patients receiving first-line tyrosine kinase inhibitors TKI.

MethodsData obtained from 63 mRCC patients who received first-line TKI between 2007 and 2013 were evaluated retrospectively. The association of PLR, NLR, and established prognostic factors with progression-free survival PFS and overall survival OS was analyzed using the Kaplan–Meier method. The influence of independent prognostic factors on survival was determined using multivariable Cox regression analysis.

ResultsHigh NLR >3.6 and PLR >150 were related to shorter PFS p = 0.001 and OS p = 0.001. The presence of brain metastases hazard ratio HR 4.94, 95% CI 1.75–13.9; p = 0.002 and high PLR >150, HR 13.1, 95% CI 5.14–33.2; p = 0.001 were independently associated with PFS, and Eastern Cooperative Oncology Group Performance status ≥2 HR 3.60, 95% CI 1.39–9.31; p = 0.008, lymph node metastasis HR 2.76, 95% CI 1.11–6.86; p = 0.029, brain metastasis HR 9.39, 95% CI 2.74–32.1; p = 0.001, and high PLR >150, HR 16.1, 95% CI 4.41–58.4; p = 0.001 with OS.

ConclusionsHigh PLR was associated with shorter survival of mRCC patients receiving first-line TKI. The PLR may be an effective independent prognostic factor in this setting.

KeywordsPlatelet–lymphocyte ratio Neutrophil–lymphocyte ratio Neoplasm metastasis Carcinoma, renal cell AbbreviationsPLRplatelet–lymphocyte ratio

NLRneutrophil–lymphocyte ratio

mRCCmetastatic renal cell cancer

TKItyrosine kinase inhibitors

CRPC-reactive protein

PFSprogression-free survival

OSoverall survival

HRhazard ratio

PSperformance status

Download fulltext PDF



Author: Tae Ju Park - Yang Hyun Cho - Ho Seok Chung - Eu Chang Hwang - Sung-Hoon Jung - Jun Eul Hwang - Woo Kyun Bae - Jin W

Source: https://link.springer.com/







Related documents